TY - JOUR
T1 - Diabetes and Cardiovascular Disease
T2 - an Update
AU - Almourani, Rajaa
AU - Chinnakotla, Bhavana
AU - Patel, Richa
AU - Kurukulasuriya, L. Romayne
AU - Sowers, James
N1 - Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Purpose of Review: Cardiovascular disease (CVD) is the leading cause of mortality in people with diabetes. Our aim was to review the pathophysiology of CVD in diabetes, review related landmark trials, and discuss the cardiovascular benefit of glucose-lowering agents. We have also discussed the role of controversial anti-platelet therapy. Recent Findings: Recent studies have shown the impact of glucose-lowering agents on CVD in people with diabetes. Statins are now recommended for all patients with diabetes over the age of 40 regardless of the LDL level given the cardiovascular benefit of these drugs. Current recommendations suggest a blood pressure < 130/80 for individuals with high cardiovascular risk. Summary: Cardiovascular risk reduction should be an important part of the management of diabetes. Focusing solely on glycemic control may not be the best therapeutic strategy. Multifactorial risk reduction should be taken into account. Lipid-lowering agents and anti-hypertensives should be a corner stone of treatment of diabetes. With currently available data, glucose-lowering agents with cardiovascular benefit should be started early in the disease process.
AB - Purpose of Review: Cardiovascular disease (CVD) is the leading cause of mortality in people with diabetes. Our aim was to review the pathophysiology of CVD in diabetes, review related landmark trials, and discuss the cardiovascular benefit of glucose-lowering agents. We have also discussed the role of controversial anti-platelet therapy. Recent Findings: Recent studies have shown the impact of glucose-lowering agents on CVD in people with diabetes. Statins are now recommended for all patients with diabetes over the age of 40 regardless of the LDL level given the cardiovascular benefit of these drugs. Current recommendations suggest a blood pressure < 130/80 for individuals with high cardiovascular risk. Summary: Cardiovascular risk reduction should be an important part of the management of diabetes. Focusing solely on glycemic control may not be the best therapeutic strategy. Multifactorial risk reduction should be taken into account. Lipid-lowering agents and anti-hypertensives should be a corner stone of treatment of diabetes. With currently available data, glucose-lowering agents with cardiovascular benefit should be started early in the disease process.
KW - Cardiovascular disease
KW - Diabetes
KW - Dyslipidemia
KW - Hypertension
KW - Legacy effect
KW - Memory effect
UR - http://www.scopus.com/inward/record.url?scp=85076431134&partnerID=8YFLogxK
U2 - 10.1007/s11892-019-1239-x
DO - 10.1007/s11892-019-1239-x
M3 - Review article
C2 - 31828525
AN - SCOPUS:85076431134
SN - 1534-4827
VL - 19
JO - Current diabetes reports
JF - Current diabetes reports
IS - 12
M1 - 161
ER -